Online inquiry

IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2707MR)

This product GTTS-WQ2707MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19&CD3E gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001178098.2; NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930; 916
UniProt ID P15391; P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2707MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ850MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ5850MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ7920MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ9105MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ10969MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ10670MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ246MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ11290MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI4893
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW